Literature DB >> 9105225

The ventilation-perfusion relation and gas exchange in mitral valve disease and coronary artery disease. Implications for anesthesia, extracorporeal circulation, and cardiac surgery.

T Hachenberg1, A Tenling, H E Hansson, H Tydén, G Hedenstierna.   

Abstract

BACKGROUND: Patients with mitral valve disease (MVD) are at greater risk for respiratory complications after cardiac surgery compared with patients with coronary artery disease (CAD). The authors hypothesized that ventilation-perfusion (VA/Q) inequality is more pronounced in patients with MVD before and after induction of anesthesia and during and after surgery when extracorporeal circulation (ECC) is used.
METHODS: In patients with MVD (n = 12) or with CAD (n = 12), VA/Q distribution was determined using the multiple inert gas elimination technique. Intrapulmonary shunt (Qs/Qr) defined as regions with VA/Q < 0.005 [% of total perfusion (Qr)], perfusion of "low" VA/Q areas (0.005 < or = VA/Q < 0.1, [% of Qr]), ventilation of "high" VA/Q regions (10 < or = VA/Q < or = 100 [% of total ventilation VE]), and dead space (VA/Q > 100 [% of VE]) were calculated from the retention/excretion data of the inert gases. Recordings were obtained while patients spontaneously breathed air in the awake state, during mechanical ventilation after induction of anesthesia, after separation of patients from ECC, and 4 h after operation.
RESULTS: Qs/Qr was low in the awake state (MVD group, 3% +/- 3%; CAD group, 3% +/- 4%) and increased after induction of anesthesia to 10% +/- 8% (MVD group, P < 0.05) and 11% +/- 7% (CAD group, P < 0.01). Qs/Qr increased further after separation from ECC (MVD group, 24% +/- 9%, P < 0.01; CAD group, 23% +/- 7%, P < 0.01). Similarly, alveolar-arterial oxygen tension difference (PA-aO2) increased from 168 +/- 54 mmHg (anesthetized state) to 427 +/- 138 mmHg after ECC (MVD group, P < 0.01) and from 153 +/- 65 mmHg to 377 +/- 101 mmHg (CAD group, P < 0.01). In both groups, PA-aO2 was correlated with Qs/Qr. Four hours after operation, Qs/Qr had decreased significantly to 8% +/- 6% (CAD group) and 10% +/- 6% (MVD group). PA-aO2 and Qs/Qr showed no significant differences between the CAD and MVD groups.
CONCLUSIONS: Qs/Qr is the main pathophysiologic mechanism of gas exchange impairment during cardiac surgery for MVD or CAD. Impairment of pulmonary gas exchange secondary to general anesthesia, cardiac surgery, and ECC are comparable for patients undergoing myocardial revascularization or mitral valve surgery.

Entities:  

Mesh:

Year:  1997        PMID: 9105225     DOI: 10.1097/00000542-199704000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  5 in total

1.  Mechanical ventilation strategies and inflammatory responses to cardiac surgery: a prospective randomized clinical trial.

Authors:  Hermann Wrigge; Ulrike Uhlig; Georg Baumgarten; Jan Menzenbach; Jörg Zinserling; Martin Ernst; Daniel Drömann; Armin Welz; Stefan Uhlig; Christian Putensen
Journal:  Intensive Care Med       Date:  2005-08-17       Impact factor: 17.440

Review 2.  Pulmonary pathophysiology and lung mechanics in anesthesiology: a case-based overview.

Authors:  Marcos F Vidal Melo; Guido Musch; David W Kaczka
Journal:  Anesthesiol Clin       Date:  2012-09-01

Review 3.  Respiratory complications in the postanesthesia care unit: A review of pathophysiological mechanisms.

Authors:  Marcin Karcz; Peter J Papadakos
Journal:  Can J Respir Ther       Date:  2013

4.  Lung Function before and Two Days after Open-Heart Surgery.

Authors:  Charlotte Urell; Elisabeth Westerdahl; Hans Hedenström; Christer Janson; Margareta Emtner
Journal:  Crit Care Res Pract       Date:  2012-08-08

5.  Effect of different dosages of nitroglycerin infusion on arterial blood gas tensions in patients undergoing on- pump coronary artery bypass graft surgery.

Authors:  Gholamreza Masoumi; Evaz Hidar Pour; Ali Sadeghpour; Mohsen Ziayeefard; Mostapha Alavi; Sanam Javid Anbardan; Shahin Shirani
Journal:  J Res Med Sci       Date:  2012-02       Impact factor: 1.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.